JP2023505169A5 - - Google Patents

Info

Publication number
JP2023505169A5
JP2023505169A5 JP2022533108A JP2022533108A JP2023505169A5 JP 2023505169 A5 JP2023505169 A5 JP 2023505169A5 JP 2022533108 A JP2022533108 A JP 2022533108A JP 2022533108 A JP2022533108 A JP 2022533108A JP 2023505169 A5 JP2023505169 A5 JP 2023505169A5
Authority
JP
Japan
Prior art keywords
seq
pharmaceutical composition
interferon
agonist
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022533108A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023505169A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2020/083737 external-priority patent/WO2021110561A1/en
Publication of JP2023505169A publication Critical patent/JP2023505169A/ja
Publication of JP2023505169A5 publication Critical patent/JP2023505169A5/ja
Pending legal-status Critical Current

Links

JP2022533108A 2019-12-03 2020-11-27 B型肝炎感染の治療における使用のためのインターフェロン会合抗原結合タンパク質 Pending JP2023505169A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP19306551 2019-12-03
EP19306551.3 2019-12-03
EP19306572 2019-12-04
EP19306572.9 2019-12-04
PCT/EP2020/083737 WO2021110561A1 (en) 2019-12-03 2020-11-27 Interferon-associated antigen binding proteins for use in treating hepatitis b infection

Publications (2)

Publication Number Publication Date
JP2023505169A JP2023505169A (ja) 2023-02-08
JP2023505169A5 true JP2023505169A5 (cg-RX-API-DMAC7.html) 2023-12-05

Family

ID=73554457

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022533108A Pending JP2023505169A (ja) 2019-12-03 2020-11-27 B型肝炎感染の治療における使用のためのインターフェロン会合抗原結合タンパク質

Country Status (10)

Country Link
US (1) US20230028476A1 (cg-RX-API-DMAC7.html)
EP (1) EP4069290A1 (cg-RX-API-DMAC7.html)
JP (1) JP2023505169A (cg-RX-API-DMAC7.html)
KR (1) KR20220109435A (cg-RX-API-DMAC7.html)
CN (1) CN115052626A (cg-RX-API-DMAC7.html)
AU (1) AU2020397416A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022010425A2 (cg-RX-API-DMAC7.html)
CA (1) CA3163356A1 (cg-RX-API-DMAC7.html)
IL (1) IL293449A (cg-RX-API-DMAC7.html)
WO (1) WO2021110561A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3163358A1 (en) 2019-12-03 2021-06-10 Evotec International Gmbh Interferon-associated antigen binding proteins and uses thereof
KR20230010251A (ko) 2020-05-13 2023-01-18 보넘 테라퓨틱스, 인크. 단백질 복합체의 조성물 및 그의 사용 방법
CA3220925A1 (en) * 2021-06-09 2022-12-15 Kara Carter Interferon-associated antigen binding proteins for use for the treatment or prevention of coronavirus infection
WO2024126294A1 (en) * 2022-12-13 2024-06-20 Evotec International Gmbh Interferon-associated antigen binding proteins for use for the treatment or prevention of parainfluenza virus infection
WO2024126293A1 (en) * 2022-12-13 2024-06-20 Evotec International Gmbh Interferon-associated antigen binding proteins for use for the treatment or prevention of respiratory syncytial virus infection
WO2024126289A1 (en) * 2022-12-13 2024-06-20 Evotec International Gmbh Interferon-associated antigen binding proteins for use for the treatment or prevention of influenza virus infection
WO2024213635A1 (en) * 2023-04-12 2024-10-17 Evotec International Gmbh Interferon-associated antigen binding proteins for use for the treatment or prevention of hepatitis delta virus infection

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
DE3681787D1 (de) 1985-07-05 1991-11-07 Whitehead Biomedical Inst Expression von fremdem genetischem material in epithelzellen.
US4980286A (en) 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
EP0281604B1 (en) 1986-09-02 1993-03-31 Enzon Labs Inc. Single polypeptide chain binding molecules
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US5750172A (en) 1987-06-23 1998-05-12 Pharming B.V. Transgenic non human mammal milk
HK1008049A1 (en) 1987-09-11 1999-04-30 Whitehead Institute For Biomedical Research Transduced fibroblasts and use therefor
ATE110108T1 (de) 1987-12-11 1994-09-15 Whitehead Biomedical Inst Genetische modifizierung von endothelialen zellen.
DE68927996T2 (de) 1988-02-05 1997-12-04 Hughes Howard Med Inst Modifizierte hepatozyten und deren anwendung
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5328470A (en) 1989-03-31 1994-07-12 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
US5633076A (en) 1989-12-01 1997-05-27 Pharming Bv Method of producing a transgenic bovine or transgenic bovine embryo
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
DE69123981T3 (de) 1990-10-31 2006-06-14 Cell Genesys Inc Nützliche retrovirale vektoren für die gentherapie
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
AU693436B2 (en) 1993-03-09 1998-07-02 Genzyme Corporation Isolation of components of interest from milk
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
GB9524973D0 (en) 1995-12-06 1996-02-07 Lynxvale Ltd Viral vectors
US6133426A (en) 1997-02-21 2000-10-17 Genentech, Inc. Humanized anti-IL-8 monoclonal antibodies
US6517529B1 (en) 1999-11-24 2003-02-11 Radius International Limited Partnership Hemodialysis catheter
WO2007130493A2 (en) * 2006-05-03 2007-11-15 Regents Of The University Of Colorado Cd40 agonist antibody/type1 interferon synergistic adjuvant combination, conjugates containing and use thereof as a therapeutic to enhance cellular immunity
BR112013002532A2 (pt) * 2010-08-05 2016-05-31 Hoffmann La Roche proteína de fusão de citocina anti-viral do anticorpo anti-mhc
CN116063494A (zh) * 2016-03-04 2023-05-05 洛克菲勒大学 具有增强的激动剂活性的cd40的抗体
WO2017176319A1 (en) * 2016-04-06 2017-10-12 University Of Washington Therapeutic vaccine for hepatitis b virus (hbv) using the hbv core antigen
WO2018087345A1 (en) * 2016-11-14 2018-05-17 F. Hoffmann-La Roche Ag COMBINATION THERAPY OF AN HBsAg INHIBITOR, A NUCLEOS(T)IDE ANALOGUE AND AN INTERFERON
WO2019229264A1 (en) * 2018-06-01 2019-12-05 Sanofi Combination therapy for treating hepatitis b virus infection

Similar Documents

Publication Publication Date Title
JP2018535650A5 (cg-RX-API-DMAC7.html)
FI4045533T3 (fi) Ihmisen monoklonaalisia vasta-aineita vakavalle akuutille koronavirus 2 -hengityselinoireyhtymälle (sars-cov-2)
JP2022548783A5 (cg-RX-API-DMAC7.html)
JP2025036561A5 (cg-RX-API-DMAC7.html)
JP2020079252A5 (cg-RX-API-DMAC7.html)
JP2022540083A5 (cg-RX-API-DMAC7.html)
JP2012504955A5 (cg-RX-API-DMAC7.html)
JP2021524267A5 (cg-RX-API-DMAC7.html)
JP2010516229A5 (cg-RX-API-DMAC7.html)
JP2018108081A5 (cg-RX-API-DMAC7.html)
JP2018521638A5 (cg-RX-API-DMAC7.html)
RU2009136677A (ru) Рекомбинантные антитела для лечения респираторно-синцитиальных вирусных инфекций
JP2023071956A5 (cg-RX-API-DMAC7.html)
JP2018035138A5 (cg-RX-API-DMAC7.html)
JP2025032102A5 (cg-RX-API-DMAC7.html)
JP2017533694A5 (cg-RX-API-DMAC7.html)
JP2011528902A5 (cg-RX-API-DMAC7.html)
RU2011105062A (ru) Нейтрализующие антитела против вируса гриппа а и их использование
JP2006512899A5 (cg-RX-API-DMAC7.html)
JP2011528901A5 (cg-RX-API-DMAC7.html)
RU2012112829A (ru) Анти-gitr-антитела
JP2017537084A5 (cg-RX-API-DMAC7.html)
RU2765878C2 (ru) Антитела для лечения инфекции гепатитом в и связанных с ней заболеваний
JP2018522540A5 (cg-RX-API-DMAC7.html)
RU2014146503A (ru) Белки, связывающие антиген - лиганд cd30 человека